The American Academy of Neurology's (AAN) Annual Meeting begins this weekend in Philadelphia. AAN 2019 is the world's largest gathering of neurologists and neurology professionals. The Michael J. Fox Foundation (MJFF) is pleased to highlight our staff, funded investigators and sponsored studies featured in posters and platforms throughout the meeting.

• Thursday, May 9, 11: 30 a.m. - 6:30 p.m., Poster P5.8-050: Exploring the experience of off in Parkinson's disease: A qualitative research approach. Lana Chahine et al.
  This poster includes findings from a study on how Parkinson's patients experience and talk about "off" episodes, when medication doesn't work well. Understanding the language patients use to describe their experience of "off" is important to effectively recognizing and treating this common symptom.

• Monday, May 6, 1:00 - 3:00 p.m., Platform S16.009: Innovative recruitment strategies increase diversity of participation in the Fox Insight longitudinal cohort. Roseanne Dobkin et al.
  This talk outlines the recruitment strategy for MJFF's online clinical study Fox Insight. It has received an award from the AAN's Diversity Officer Workgroup recognizing "that it addresses and/or contributes to the diversity efforts in neurology."

• Tuesday, May 7, 9:15 -11:30 a.m., Plenary Session Plen02.001: A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson's disease (STEADY-PD III): Final study results. Tanya Simuni et al.
  At this plenary, researchers present the results of a Phase 3 clinical trial of isradipine in Parkinson's patients. MJFF funded some biosample collection and the preceding Phase 2 study.

Additional Highlights

• Sunday, May 5, 11:30 a.m. - 6:30 p.m., Poster P1.8-029: Longitudinal outcomes of LRRK2 gene mutation parkinsonism undergoing either Subthalamic Nucleus (STN) or Globus Pallidus Internus (GPi) Deep-Brain stimulation (DBS): a multi-group comparison. Katherine Leaver et al.
• Sunday, May 5, 3:30 - 5:30 p.m., Platform S10.005: Longitudinal characterization of the clinical and DAT characteristics of participants with scans without evidence of dopaminergic deficit (SWEDDS): PPMI cohort. Kenneth Marek et al.
• Monday, May 6, 11:30 a.m. - 6:30 p.m., Poster P2.8-011: Assessing tele-health outcomes in multiyear extensions of Parkinson's disease trials (AT-HOME PD): Initiation of long-term observational study. Ruth Schneider et al.
• Monday, May 6, 11:30 a.m. - 6:30 p.m., Poster P2.8-010: Critical Path for Parkinson's: Catalyzing innovation for Parkinson's clinical trials through data sharing and regulatory science. Diane Stephenson et al.
• Monday, May 6, 11:30 a.m. - 6:30 p.m., Poster P2.8-008: Patient-centered clinical trial design: A case study in Parkinson's disease. Katrina Gwinn et al.
• Tuesday, May 7, 11: 30 a.m. - 6:30 p.m., Poster P3.8-035: NILO-PD: A phase 2A study of nilotinib in patients with advanced and early Parkinson's disease, study design and status update. Tanya Simuni et al.
• Tuesday, May 7, 11:30 a.m. - 6:30 p.m., Poster P3.8-006: Video research visits for atypical parkinsonian syndromes among Fox Trial Finder participants. Christopher Tarolli et al.
• Wednesday, May 8, 3:30 - 5:30 p.m., Platform S41.005: Clinical and imaging characteristics of non-manifest LRRK2 and GBA carriers: The PPMI cohort. Andrew Siderowf et al.
• Thursday, May 9, 11:30 a.m. - 6:30 p.m., Poster P5.8-024: What bothers Parkinson patients: Clinical curation of their verbatim reports. Lakshmi Arbatti et al.